Propanorm

Quick links to important sections

Propanorm

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Propanorm

Quick Facts

Property Description
Active Ingredient Propafenone hydrochloride
Form Tablet, prolonged-release capsule
Pharmacological Class Class IC Antiarrhythmic Agent
General Purpose Stabilizes and maintains heart rhythm
Origin Synthetic compound

What is Propanorm and its Core Identity?

Propanorm is a prescription medication whose core component is the active ingredient propafenone hydrochloride, a synthetic compound. This medicine is defined as a single active ingredient product, typically administered via the oral route as a film-coated tablet or a specialized prolonged-release capsule. The compound is a racemic mixture.

Classification: What Type of Antiarrhythmic Agent is Propafenone?

Propafenone is classified as an antiarrhythmic medication, specifically designated as a Vaughan Williams Class IC antiarrhythmic agent. This classification indicates that the drug primarily functions as a potent sodium channel blocker within the heart muscle cells (myocardium). This mechanism is clinically recognized for its efficacy in controlling supraventricular tachycardias and restoring a normal heart rhythm.

General Purpose: What does Propafenone Help to Achieve?

The general purpose of the Propafenone medication is to help restore and maintain a more stable and consistent heart rhythm. The primary therapeutic function of the drug is to restore normal sinus rhythm in patients experiencing atrial fibrillation or flutter. This action controls fast, chaotic, or irregular electrical activity by exerting a membrane-stabilizing effect on the heart cells, allowing the heart to function more rhythmically and efficiently.

What side effects are possible with Propanorm?

Possible Side Effects and Safety Information

The safety profile of Propanorm (propafenone hydrochloride) is structured by regulatory authorities based on the frequency and the physiological systems affected. These official classifications describe the possible adverse reactions documented during clinical use and post-marketing surveillance. The risk of side effects is categorized using standard frequency terminology.


Frequency-Classified Adverse Reactions

Classification Examples of Documented Reactions
Very Common (ge 1/10) Dizziness, Nausea, Taste disturbance (dysgeusia)
Common (ge 1/100 to < 1/10) Headache, Anxiety, Sleep disorders, Bradycardia, Vomiting, Constipation, Blurred vision
Uncommon (ge 1/1,000 to < 1/100) Syncope, Thrombocytopenia, Hypotension, Vertigo

System-Organ-Class Safety

Adverse reactions are officially grouped into System-Organ Classes (SOCs), with the most critical being Cardiac disorders. These include the documented risk of proarrhythmia (aggravation of pre-existing arrhythmia), cardiac failure, and disturbances in cardiac conduction (e.g., atrioventricular block). Other affected SOCs include Nervous system disorders, Gastrointestinal disorders, and, rarely, Blood and lymphatic system disorders (e.g., agranulocytosis).


Serious Adverse Reactions and Restrictions

The most clinically significant safety concern documented in regulatory labeling is the potential for proarrhythmia and the occurrence of cardiac failure. Furthermore, specific safety-related restrictions apply to its use: the drug is generally restricted for patients with uncontrolled congestive heart failure or structural heart disease. Population-specific considerations also exist, noting that patients with severe hepatic or renal impairment require attention due to the potential for increased drug accumulation. Gastrointestinal and neurological effects are noted in the label as more frequently observed at the start of treatment or during dose changes.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Propafenone hydrochloride (Propanorm) is officially classified as a medical emergency, and regulatory guidance mandates seeking immediate medical attention upon suspicion. The official documentation emphasizes the potential for severe, life-threatening cardiovascular toxicity, which may present as cardiac arrest, cardiovascular shock, ventricular fibrillation, marked QRS widening, bradycardia, or AV block.

Overdose manifestations also involve the central nervous system (CNS), with documented presentations including convulsions (seizures), somnolence, dizziness, and severe vomiting. Due to these critical risks, close clinical and continuous Electrocardiogram (ECG) monitoring is required in a hospital setting.

Regarding management, official labeling states that no specific antidote is known for Propafenone toxicity, and treatment is symptomatic and supportive. For the management of severe conduction disturbances associated with compromised cardiac function, procedural interventions like pacemaker therapy, atropine, or isoprenaline may be necessary. Furthermore, patients with impaired hepatic or renal function are noted to require careful monitoring for signs of overdosage due to the risk of drug accumulation.

Therapeutic Uses of Propanorm

Therapeutic Uses of Propanorm

Propanorm is a medication classified as a Class IC antiarrhythmic agent. Its primary function is to stabilize the electrical activity of the heart to maintain a regular rhythm. It is typically prescribed for the management and prevention of specific types of irregular heartbeats (arrhythmias).

Core Indications

The medication is used to address various supraventricular and ventricular rhythm disturbances, including:

  • Atrial Fibrillation: Propanorm is used to prevent the recurrence of paroxysmal atrial fibrillation, a condition characterized by rapid and irregular heartbeats originating in the upper chambers of the heart.
  • Atrial Flutter: It helps manage paroxysmal atrial flutter, ensuring the heart maintains a more consistent rhythm.
  • Paroxysmal Supraventricular Tachycardia (PSVT): This includes conditions like Wolff-Parkinson-White syndrome, where the medication is used to prevent episodes of sudden, rapid heart rates.
  • Ventricular Arrhythmias: In specific clinical scenarios, it is utilized to treat documented life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia.

Mechanism and Benefits

Propanorm works by blocking sodium channels in the heart muscle cells. This action slows the conduction of electrical impulses, which helps to:

  • Restore Normal Rhythm: By interfering with the abnormal electrical signals that cause palpitations, the medication helps the heart return to a steady, sinus rhythm.
  • Reduce Frequency of Episodes: For patients with paroxysmal conditions, the primary benefit is a significant reduction in the frequency and severity of symptomatic episodes.
  • Improve Quality of Life: By stabilizing the heart rate, the medication can alleviate symptoms associated with arrhythmias, such as shortness of breath, dizziness, and chest discomfort.

Eligibility and Restrictions for Use

Eligibility and Contraindications

Propanorm (propafenone) is an antiarrhythmic drug for specific heart rhythm conditions, and its use is strictly defined by regulatory guidelines based on a patient's overall cardiac health.

Do Not Use (Contraindicated):

  • Structural Heart Disease: It is contraindicated in patients with underlying structural heart disease (e.g., heart failure, cardiogenic shock), as this significantly increases the risk of serious new or worsened arrhythmias (proarrhythmia).
  • Conduction Issues: It must not be used in patients with pre-existing Sinoatrial, Atrioventricular, or Intraventricular conduction disorders (like Sick Sinus Node Syndrome or AV block) unless an artificial pacemaker is present.
  • Other Conditions: Contraindicated in patients with marked hypotension (low blood pressure), known Brugada Syndrome, severe obstructive pulmonary disease or bronchospastic disorders, and marked electrolyte imbalance.

Use is Restricted or Requires Caution:

  • Lesser Arrhythmias: Its use for less severe or non-life-threatening ventricular arrhythmias is generally not recommended.
  • Organ Impairment: Use with caution in patients with significant hepatic (liver) or renal (kidney) impairment, as this can affect how the medicine is cleared from the body.
  • Pediatric Patients: Safety and efficacy have not been formally established in the pediatric population.
  • Drug Interactions: Simultaneous use with both a CYP2D6 inhibitor and a CYP3A4 inhibitor is restricted due to the potential for significantly increased propafenone levels.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Propafenone's interaction profile is shaped by its extensive metabolism and its ability to inhibit the clearance of co-administered medicines. Co-administration is formally contraindicated with the simultaneous use of both a CYP2D6 inhibitor and a CYP3A4 inhibitor, a combination documented to significantly increase Propafenone plasma concentrations and heighten the risk of serious cardiac effects. High doses of Ritonavir are also explicitly restricted for co-administration.

Propafenone is metabolized by the CYP2D6, CYP3A4, and CYP1A2 enzymes. Substances that inhibit these pathways, such as Ketoconazole or Quinidine, increase Propafenone plasma levels, while enzyme inducers, like Rifampin, decrease its concentration. Propafenone itself inhibits the clearance of other medicines, necessitating the official monitoring of plasma levels for co-administered substances. This includes Digoxin, whose serum levels are documented to increase by 35% to 85%, and Warfarin, which sees a corresponding increase in Prothrombin Time. The plasma levels of beta-blockers, including Metoprolol and Propranolol, are also officially documented to be raised.

Interaction severity is noted to be increased in patients who are CYP2D6 Poor Metabolizers, particularly when combined with a CYP3A4 inhibitor. Furthermore, the consumption of Grapefruit Juice is advised against because it is documented to increase Propafenone exposure.

Mechanism of Action

Mechanism of Action: Electrophysiological Modulation

Propafenone acts primarily as a Class IC antiarrhythmic agent by selectively inhibiting voltage-gated sodium channels in myocardial cell membranes. This interaction restricts the rapid influx of sodium ions (Na^+) during the depolarization phase (Phase 0) of the cardiac action potential.

The resulting kinetic effect is a pronounced reduction in electrical impulse conduction velocity throughout the atrial and ventricular tissues. The diminished velocity increases the time required for signal propagation, thereby modifying the conditions necessary for continuous re-entrant activation circuits.

Propafenone also engages a secondary mechanism through weak antagonism of beta-adrenergic receptors (beta1). This action reduces the binding of endogenous catecholamines (like adrenaline) to the receptor, which consequently dampens the sympathetic influence on the heart. This physiological consequence manifests as a decrease in the spontaneous rate and excitability of cardiac pacemaker cells. Additionally, the compound exhibits a modest, concentration-dependent interaction with specific potassium channels, which contributes to a slight prolongation of the effective refractory period in cardiac tissue.

Dosage and Administration Information

Official Administration Instructions

Propanorm (propafenone hydrochloride) is administered exclusively via the oral route and is available as an immediate-release (IR) tablet and an extended-release (ER) capsule. The standard approach to use involves individualized titration, starting with a low dose and gradually increasing the amount over time to establish a stable regimen.


Dosing Frequency and Adjustment

The required dosing frequency is determined by the formulation. The IR tablet is typically initiated at 150 mg and taken three times daily, with dose increases occurring at minimum intervals of 3 to 4 days. The maximum daily dose for this form is 900 mg. The ER capsule is administered twice daily, and its titration increases must be separated by a minimum of 5 days.


Special Administration Conditions

Administration instructions specify certain handling constraints. While IR tablets are often recommended to be taken after food, ER capsules can be taken with or without food. A critical procedural instruction is that the ER capsule must be swallowed whole and cannot be crushed, broken, or chewed to preserve its controlled-release properties. Initiation of therapy for serious arrhythmias is often required to occur under hospital surveillance.


Population Adjustments

Specific adjustments are mandated for certain patient groups. For individuals with impaired liver function (hepatic impairment), a substantial dose reduction to approximately 20% to 30% of the usual oral dose is required. Treatment in older adults must also employ a slower, more cautious titration schedule. If a dose is missed, the standard procedure is to take the next scheduled dose at the usual time and not to take a double dose.

Recent Clinical Evidence

Research evidence / Overview of Studies for Propanorm


Evidence for Use in Paroxysmal Atrial Fibrillation and Flutter

Propafenone hydrochloride was studied for its use in managing paroxysmal atrial fibrillation (PAF) and atrial flutter. Researchers designed short-term Randomized Controlled Trials (RCTs) focusing on measurements related to the restoration of a normal heart rhythm (sinus rhythm) in patients whose symptoms had recently begun. Other long-term RCTs research examined the prevention of recurrent symptoms over periods up to a year. The populations observed in these studies were primarily adults with symptomatic PAF/flutter and who generally did not have significant underlying structural heart disease.

Acute conversion trials findings describe patterns observed in the studies related to the rate of rhythm restoration observed within defined, short time intervals (typically a few hours). Prophylactic studies data show patterns related to the frequency of arrhythmia recurrence and the measured time that elapsed before an episode returned during the observed periods.

Research for Documented Life-Threatening Ventricular Arrhythmias

Investigators research examined propafenone hydrochloride in patients with documented high-grade ventricular arrhythmias. Trials were structured as controlled and dose-ranging studies, where the primary focus was studied for suppressing the frequency of abnormal heartbeats, such as Ventricular Premature Contractions (VPCs) and Ventricular Tachycardia (VT) episodes.

Short-term trials findings describe patterns observed in the studies regarding the suppression of ventricular ectopic activity compared to a starting point or baseline. Findings data show patterns related to a reduction in the frequency of VT beats during the observed intervals.

What Research Remains Unclear or Limited

The evidence landscape highlights several key gaps. A major area where certainty remains low is the ultimate impact on hard clinical outcomes like overall survival (mortality) in patients with ventricular arrhythmias, as most research focused on temporary changes in heart rhythm patterns. Additionally, limited information for long-term outcomes exists, particularly for periods exceeding one year. Evidence is limited for patients with chronic or permanent atrial fibrillation, and research for those with significant underlying structural heart disease is constrained, as these groups were often excluded from the primary RCTs.

Frequently Asked Questions (FAQ)

Common questions about Propanorm (FAQ)


Q: How is Propanorm different from other heart medications?

Official product information states that Propanorm is classified as a Class IC antiarrhythmic agent. This means its main action is to work as a sodium channel blocker in the heart, slowing the speed of electrical signals. This mechanism is different from how many other heart medications, such as beta-blockers or calcium channel blockers, primarily function.


Q: How long does it typically take for Propanorm to start working?

Studies reviewed in regulatory documents indicate that the effect of restoring a normal heart rhythm (sinus rhythm) is often measured within the first few hours during acute treatment. However, a full therapeutic level is established via a process of dose titration conducted over a period of days under medical supervision.


Q: Is it safe to take supplements like magnesium or potassium with Propanorm?

According to official documentation, Propanorm is contraindicated (should not be used) in people with a marked electrolyte imbalance—which involves levels of minerals like potassium and magnesium. The use of any supplements that influence these mineral levels is restricted or requires consultation with a healthcare professional.


Q: What are the signs of a serious interaction involving Propanorm?

Regulatory documents list the risks of serious cardiac effects, such as a new or worsened heart rhythm (proarrhythmia) or heart failure, especially when the drug is combined with certain interacting medicines. Patients are monitored for these outcomes, and they represent the most clinically significant safety concerns.


Q: Is Propanorm safe for use in older adults (seniors)?

The official product information notes that use in older adults requires a slower and more cautious dose adjustment schedule. This population may be more susceptible to adverse effects, often due to potential decreases in liver or kidney function that can influence how the medicine is cleared from the body.


Q: Does Propanorm require regular blood tests or monitoring?

Yes, official guidance requires monitoring of the blood plasma levels for certain other medicines (like digoxin) that are taken at the same time as Propanorm. Additionally, due to its effect on the heart's electrical system, patients may require frequent checks of their heart function, such as with an ECG or EKG.


Q: Does Propanorm affect the liver or kidneys?

Official guidelines mandate that the prescribed amount must be substantially reduced for individuals who already have impaired liver function (hepatic impairment). Caution is also required for those with kidney impairment, as these organs are responsible for clearing the medicine from the body.


Q: What is the expected long-term effect of taking Propanorm?

Clinical studies reviewed by regulatory bodies suggest that side effects are frequent during long-term therapy but are generally mild and related to the amount taken. Data concerning long-term clinical outcomes, such as overall survival and effects extending beyond one year, is described as limited in current research.


Q: Is it true that Propanorm can be used 'as needed' in some cases?

While the standard use is a regular, continuous dosing schedule (taken multiple times daily), clinical trials have investigated the drug for acute conversion of heart rhythm. This refers to a short-term strategy intended to restore a normal rhythm quickly, which is carried out under specific medical supervision.


Q: Can Propanorm affect the results of an EKG or other cardiac tests?

Yes, the drug's fundamental function, described in its mechanism of action, is to slow electrical conduction within the heart. Therefore, it is expected that the medication will alter the heart’s electrical activity and the resulting parameters measured by cardiac tests like the ECG (EKG).


Q: Is it common to feel tired when first taking Propanorm?

Official product information lists tiredness (fatigue or lethargy) as a common or frequently reported adverse reaction. Neurological effects are also noted as being observed more frequently when treatment is first started or when the amount is changed.


Q: Can I drink alcohol while taking Propanorm?

Regulatory information indicates a reported interaction with alcohol, which is generally classified as moderate. Specific guidance regarding alcohol consumption while using this medication is determined by a healthcare provider.


Q: Are there restrictions on driving or operating machinery while taking Propanorm?

Yes, official European product information advises caution because adverse effects like dizziness, blurred vision, and sleep disorders may occur. These effects can impact a person's ability to perform tasks requiring alertness, and regulatory information advises caution.


Q: Can women who are pregnant or planning to be pregnant use Propanorm?

Official documentation states that the drug should be used during pregnancy only if the potential benefit to the mother is considered to outweigh the potential risk to the fetus. This is because human data is limited and animal studies have shown potential for harm.


Q: Is Propanorm usage considered safe while breastfeeding?

Regulatory information confirms that the drug is excreted into human milk. The official product information indicates that the choice to discontinue nursing or discontinue the medication requires medical consultation.


Q: Is it normal to have a dry mouth while using Propanorm?

Yes, according to adverse event listings in official regulatory documents, dry mouth is listed as a common side effect reported during the use of this medication.


Q: What if I have an allergic reaction to Propanorm?

The medicine is officially contraindicated (should not be used) in those with a known history of hypersensitivity (allergy) to the drug. The risk of hypersensitivity necessitates that signs of a serious reaction, such as swelling or difficulty breathing, are managed by medical professionals.


Q: How quickly is Propanorm eliminated from the body?

Official regulatory documents indicate that elimination of the parent drug varies greatly but has a half-life of approximately two to ten hours in most people. It is important to note that the body also produces an active metabolite of the drug which must also be eliminated.


Q: Is Propanorm a controlled substance?

Official government schedules confirm that propafenone is not classified as a controlled substance under the US Controlled Substances Act.


Q: Are there any ongoing clinical trials for new uses of Propanorm?

Publicly accessible, government-managed clinical trials databases indicate that there are ongoing or recruiting studies involving propafenone for conditions such as ventricular complexes and stroke prevention in patients with atrial fibrillation.


Q: Can Propanorm affect my sexual health?

Regulatory documents from some authorities list changes in sperm count or impotence as documented adverse reactions reported by patients during clinical use of the medication.


Q: What should I do if I accidentally take two doses of Propanorm?

Official labeling includes a description of symptoms related to overdosage. These symptoms may include severely low blood pressure, a dangerously slow heartbeat, or sedation. The potential for these severe effects requires evaluation by a medical professional.


Q: Does Propanorm interact with antacids or heartburn medication?

Official data indicates that co-administration with some medications used for heartburn may increase the risk of serious cardiac rhythm problems. This is due to the potential for these other medicines to increase the blood plasma levels of Propanorm.

How should Propanorm be stored and disposed of?

How to Store and Dispose of Propanorm (Propafenone Hydrochloride)

Propafenone hydrochloride must be stored under specific environmental and container conditions to ensure its stability, as required by official regulatory labeling.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Protection Keep away from excess heat and moisture.
Container Must be kept in the original container and tightly closed.
Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Propanorm should be disposed of through an authorized drug take-back program. If a take-back option is unavailable, the product must be mixed with an undesirable substance, sealed in a bag, and discarded in the household trash. The medicine must not be flushed down the toilet or poured down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Propanorm found in:

A-Z Index: